Advances in the Clinical Application of Novel PCSK9 Inhibitors for High-Risk Atherosclerotic Cardiovascular Disease
Clinical guidelines, including China-specific recommendations, support the use of PCSK9 inhibitors to lower LDL-C and further reduce CV risk for patients with very-high-risk or high-risk ASCVD.
Yu-Jie Fang
· International Journal of Bio... · 0 citations